ADMA Biologics, Inc, a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone201-478-5552
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$16.99 million
Profitability
Miscellaneous
Employees314
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
ADMA Biologics (NASDAQ:ADMA) Frequently Asked Questions
What is ADMA Biologics' stock symbol?
ADMA Biologics trades on the NASDAQ under the ticker symbol "ADMA."
How were ADMA Biologics' earnings last quarter?
ADMA Biologics Inc (NASDAQ:ADMA) announced its quarterly earnings data on Thursday, August, 8th. The biotechnology company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.04. The biotechnology company earned $6.56 million during the quarter, compared to analysts' expectations of $4.36 million. ADMA Biologics had a negative net margin of 323.54% and a negative return on equity of 214.26%. View ADMA Biologics' Earnings History.
When is ADMA Biologics' next earnings date?
What price target have analysts set for ADMA?
6 equities research analysts have issued 1 year price targets for ADMA Biologics' stock. Their forecasts range from $4.00 to $14.00. On average, they expect ADMA Biologics' share price to reach $10.20 in the next year. This suggests a possible upside of 127.7% from the stock's current price. View Analyst Price Targets for ADMA Biologics.
What is the consensus analysts' recommendation for ADMA Biologics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ADMA Biologics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ADMA Biologics.
What are Wall Street analysts saying about ADMA Biologics stock?
Here are some recent quotes from research analysts about ADMA Biologics stock:
- 1. Maxim Group analysts commented, "ADMA announced (8/22) that the relaunch of BIVIGAM has commenced. BIVIGAM is available through authorized distributor BioCareSD (Private). Launch for ASCENIV should follow in 2H19." (8/27/2019)
- 2. HC Wainwright analysts commented, "We note that Perceptive Credit Holdings is an investment entity of Perceptive Life Advisors, which is one of ADMA’s largest institutional shareholders. In our view, Perceptive’s extension of credit to ADMA underscores the investor’s confidence in the company." (2/21/2019)
Has ADMA Biologics been receiving favorable news coverage?
Headlines about ADMA stock have been trending somewhat positive this week, InfoTrie reports. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. ADMA Biologics earned a coverage optimism score of 0.8 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for ADMA Biologics.
Who are some of ADMA Biologics' key competitors?
Some companies that are related to ADMA Biologics include Alector (ALEC), Editas Medicine (EDIT), Sangamo Therapeutics (SGMO), Aerie Pharmaceuticals (AERI), Fate Therapeutics (FATE), BAVARIAN NORDIC/S (BVNRY), SpringWorks Therapeutics (SWTX), Twist Bioscience (TWST), NanoString Technologies (NSTG), Rubius Therapeutics (RUBY), AVITA MED LTD/S (RCEL), Atara Biotherapeutics (ATRA), Vericel (VCEL), Osiris Therapeutics (OSIR) and Krystal Biotech (KRYS).
What other stocks do shareholders of ADMA Biologics own?
Who are ADMA Biologics' key executives?
ADMA Biologics' management team includes the folowing people:
- Mr. Adam S. Grossman, Co-Founder, Pres, CEO & Director (Age 42)
- Dr. Jerrold B. Grossman Ph.D., D.P.S., Co-Founder & Vice Chairman (Age 71)
- Mr. Brian Lenz CPA, CPA, Exec. VP & CFO (Age 47)
- Dr. James Mond, Exec. VP, Chief Scientific Officer & Chief Medical Officer (Age 73)
- Mr. James Hauert, Sr. VP of Commercialization & Strategy
How do I buy shares of ADMA Biologics?
Shares of ADMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is ADMA Biologics' stock price today?
One share of ADMA stock can currently be purchased for approximately $4.48.
How big of a company is ADMA Biologics?
ADMA Biologics has a market capitalization of $265.75 million and generates $16.99 million in revenue each year. The biotechnology company earns $-65,740,000.00 in net income (profit) each year or ($1.45) on an earnings per share basis. ADMA Biologics employs 314 workers across the globe.View Additional Information About ADMA Biologics.
What is ADMA Biologics' official website?
How can I contact ADMA Biologics?
ADMA Biologics' mailing address is 465 STATE ROUTE 17, RAMSEY NJ, 07446. The biotechnology company can be reached via phone at 201-478-5552 or via email at [email protected]
MarketBeat Community Rating for ADMA Biologics (NASDAQ ADMA)
MarketBeat's community ratings are surveys of what our community members think about ADMA Biologics and other stocks. Vote "Outperform" if you believe ADMA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADMA will underperform the S&P 500 over the long term. You may vote once every thirty days.
